drugset
drugset / Trial / NCT05814159

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

NCT05814159 ↗

Phase 3 Active not recruiting 15 enrolled Swedish Orphan Biovitrum CMIC Co, Ltd. Japan · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis \[SJIA\] and Adult-onset Still's disease \[AOSD\]).

Timeline

Start
2022-08-24
Primary completion
2025-12-10
Completion
2026-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 2 mg/kg Subcutaneous
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications

adult-onset Still disease systemic-onset juvenile idiopathic arthritis